{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-26-000013","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.764063+00:00","generated_at":"2026-05-15T17:53:18.939395+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas Medicine Q4 2025 net loss $5.6M; EDIT-401 IND on track mid-2026","bullets":["Cash $146.6M at Dec 31, 2025, down from $269.9M; runway into Q3 2027.","Net loss Q4 2025 $5.6M ($0.06/sh) vs $45.4M ($0.55/sh) in Q4 2024.","Full year 2025 net loss $160.1M ($1.80/sh) vs $237.1M ($2.88/sh) in 2024.","Lead candidate EDIT-401 achieved >90% mean LDL-C reduction in preclinical; IND/CTA submission expected by mid-2026.","First-in-human trial in HeFH planned for 2026; early proof-of-concept data targeted by year-end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-26-000013","json":"https://secwatch.observer/filing/0001650664-26-000013.json","markdown":"https://secwatch.observer/filing/0001650664-26-000013.md","text":"https://secwatch.observer/filing/0001650664-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000013/0001650664-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000013/edit-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:53:18.939395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}